U.S. Markets closed

Allergan plc (AGN)


NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
246.71+0.62 (+0.25%)
At close: 4:02PM EDT

246.71 0.00 (0.00%)
After hours: 5:50PM EDT

People also watch
BIIBCELGVRXGILDREGN
Full screen
Previous Close246.09
Open247.37
Bid230.00 x 100
Ask247.90 x 100
Day's Range246.21 - 249.21
52 Week Range184.50 - 261.27
Volume1,713,052
Avg. Volume2,301,093
Market Cap82.86B
Beta1.27
PE Ratio (TTM)7.69
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield2.80 (1.12%)
Ex-Dividend Date2017-05-16
1y Target EstN/A
Trade prices are not sourced from all markets
  • Reuters39 minutes ago

    Sarepta appoints former Allergan executive Douglas Ingram as CEO

    Sarepta Therapeutics Inc said on Wednesday it appointed Douglas Ingram as president and chief executive officer. Ingram, who previously held a senior executive position in Allergan Plc, will also be a ...

  • Morningstar11 hours ago

    Healthcare: ACA Repeal Efforts Unlikely to Yield Major Legislative Changes

    While the Republican-led Congress continues the push to repeal the Affordable Care Act, we still see challenges in passing any new legislation.

  • Barrons.comyesterday

    Valeant: Out of the Frying Pan, Into the Fire

    Shares of Valeant Pharmaceuticals International (VRX) spiked yesterday on speculation regarding a possible debt-to-equity swap by the troubled drug maker. Wells Fargo analyst David Maris weighed in on the notion today, arguing that even if a swap does happen, it does not repair poor business trends or the increasingly unlikelihood that Valeant can deliver the strong earnings growth promised by consensus forecasts. As Maris writes: Based on our experience and feedback from our high yield debt analyst, we think that most debt holders do not have the ability or interest to take cross structure risk.